Clinical trial NCT00251394: Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma
Official title: A Phase 2, Open-Label Study of the Efficacy, Safety, and Tolerability of Dynavax's Immunostimulatory Phosphorothiolate Oligodeoxyribonucleotide, 1018 ISS, Following Rituxan (Rituximab) Treatment in Patients With CD20+, B-Cell Follicular Non-Hodgkin's Lymphoma.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Non-Hodgkin's Lymphoma
Keywords: B-Cell follicular non-Hodgkin's lymphoma
Rituxan
Rituximab
1018 ISS
CD 20 +
Lead sponsor: Dana-Farber Cancer Institute
Sponsor class: OTHER
Collaborators: name: Dynavax Technologies Corporation
name: James P. Wilmot Cancer Center
name: University of Rochester
name: Brigham and Women's Hospital
name: Massachusetts General Hospital
First posted: 2005-11-10
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to determine the effects (good and bad) and the safety of Dynavax's immunostimulatory phosphorothiolate oligodeoxyribonucleotide (1018 ISS) given in combination with Rituxan on patients with B-cell follicular non-Hodgkin's lymphoma. This research is being done because recurrent follicular non-Hodgkin's lymphoma is not curable with standard chemotherapy or antibody treatments. 1018 ISS is an experimental compound that consists of short pieces of DNA that stimulate the immune system. It is hoped that 1018 ISS may improve the ability of Rituxan to kill cancer cells.

Detailed description: * Patients will receive four weekly infusions of Rituxan which is standard treatment for B-cell non-Hodgkin's lymphoma. Approximately 30 to 60 minutes after the second, third and fourth infusions of Rituxan, the patient will receive up to 3 injections of 1018 ISS under the skin. The number of injections will depend upon the patients weight. One week after the last Rituxan infusion the patient will receive a fourth and final injection of 1018 ISS.
* After completion of the 5-week treatment period, a physical examination and blood work will be performed. The patient will also be examined to see if the tumor has gotten smaller, bigger, or stayed the same size and in the same places by either CT scan or MRI. A bone marrow aspiration and biopsy will be done to examine any changes in bone marrow cells.
* The following tests will be performed to determine whether or not a patient is eligible to participate in this clinical study: Bone marrow aspiration and biopsy; lymph node biopsy; skin biopsy; standard x-ray tests (x-rays, CT scans, MRI, ultrasounds, and/or radioactive drug scans); and blood work.
* While receiving treatment patients will have the following procedures done; Physical examination once a week for 4 weeks, blood testing for any changes in the blood, blood chemistry and other blood components. Patients will also be requested to keep a diary between each study visit to record any health changes or any over-the-counter medication or herbal preparation they may have taken.

Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Pathological evidence of CD20+, B-cell follicular non-Hodgkin's lymphoma
* Received at least one previous chemotherapy regimen for lymphoma
* Hemoglobin \> 8.5 g/dl
* WBC \> 2,000/mm3
* ANC \> 1,000/mm3
* Platelet count \> 75,000/mm3
* ECOG performance status of less than or equal to 2
* Life expectancy of greater than 4 months
* Women and men of childbearing potential must be willing to use highly effective methods of birth control for duration of time on the study

Exclusion Criteria:

* Pregnant of lactating women
* Treatment with chemotherapy, including systemic steroids, or radiation therapy within 30 days
* Current use of systemic or inhaled steroids
* Treatment with radioimmunotherapy, autologous stem cell transplantation, or fludarabine within 6 months
* Disease progression within 6 months of any previous rituximab therapy
* History of allogenic transplantation, including nonmyeloablative transplantation
* Unstable angina, symptomatic cardiac arrhythmia or clinical heart failure
* Severe pulmonary disease, symptomatic pleural effusions, or clinically significant pulmonary symptoms
* Active infection requiring systemic antibiotic, antiviral, or antifungal therapy
* Clinically apparent CNS lymphoma
* Major surgery within 2 weeks
* Known human anti-murine antibody (HAMA) or human anti-chimeric antibody (HACA) response
* Known Hepatitis B surface antigen positive
* History of autoimmune disorder
* Current therapeutic use of anticoagulants
* History of coagulopathy
* Known allergy to any of the components of 1018 ISS or Rituxan
* Participation in another investigational trial within 30 days
* Any clinically significant abnormality in screening blood chemistry, hematology, or urinalysis

Primary outcomes:
measure: To determine the proportion of patients who are alive and without disease progression 1 year after initiating Rituxan plus 1018 ISS therapy.
timeFrame: 2 years
Secondary outcomes:
measure: To assess the overall response rate following treatment
timeFrame: 2 years
measure: to determine duration of response and time to progression
measure: to further define the safety profile of 1018 ISS
timeFrame: 2 years
measure: to explore the biologic activity of 1018 ISS.
timeFrame: 2 years
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana-Farber Cancer Institute
state: Massachusetts
Study officials:
affiliation: Dana-Farber Cancer Institute
name: Arnold Freedman, MD
role: PRINCIPAL_INVESTIGATOR
References: